Elanco Animal Health Inc. Receives USDA Approval for TruCan Ultra CIV Canine Influenza Vaccine, Enhancing Dog Respiratory Protection

Reuters

07/09

<a href="https://laohu8.com/S/ELAN">Elanco Animal Health Inc</a>. Receives USDA Approval for TruCan Ultra CIV Canine Influenza Vaccine, Enhancing Dog Respiratory Protection

Elanco Animal Health Inc. has received approval from the U.S. Department of Agriculture (USDA) for its TruCan Ultra CIV H3N2/H3N8, a canine influenza vaccine. This vaccine offers broad respiratory protection against the H3N2 and H3N8 strains, making it the only ½ mL bivalent Canine Influenza Virus (CIV) vaccine available with such comprehensive coverage. With 100% virus neutralization against 33 current field isolates and zero lung lesions observed in vaccinated dogs post H3N2 challenge, TruCan Ultra CIV completes Elanco's Tru Portfolio of vaccines. This approval underscores Elanco's commitment to providing innovative animal health solutions, enhancing the health and happiness of pets and their owners.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elanco Animal Health Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DE25259) on July 09, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2550313637"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2550313637\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2550313637?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-09 20:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2550313637","market":"us","top_or_hot":-1,"title":"Elanco Animal Health Inc. Receives USDA Approval for TruCan Ultra CIV Canine Influenza Vaccine, Enhancing Dog Respiratory Protection","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ELAN\">Elanco Animal Health Inc</a>. Receives USDA Approval for TruCan Ultra CIV Canine Influenza Vaccine, Enhancing Dog Respiratory Protection\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ELAT\">Elanco Animal Health</a> Inc. has received approval from the U.S. Department of Agriculture (USDA) for its TruCan Ultra CIV H3N2/H3N8, a canine influenza vaccine. This vaccine offers broad respiratory protection against the H3N2 and H3N8 strains, making it the only ½ mL bivalent Canine Influenza Virus (CIV) vaccine available with such comprehensive coverage. With 100% virus neutralization against 33 current field isolates and zero lung lesions observed in vaccinated dogs post H3N2 challenge, TruCan Ultra CIV completes Elanco's Tru Portfolio of vaccines. This approval underscores Elanco's commitment to providing innovative animal health solutions, enhancing the health and happiness of pets and their owners.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elanco Animal Health Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DE25259) on July 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Elanco Animal Health Inc. Receives USDA Approval for TruCan Ultra CIV Canine Influenza Vaccine, Enhancing Dog Respiratory Protection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nElanco Animal Health Inc. Receives USDA Approval for TruCan Ultra CIV Canine Influenza Vaccine, Enhancing Dog Respiratory Protection\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-09 20:27</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ELAN\">Elanco Animal Health Inc</a>. Receives USDA Approval for TruCan Ultra CIV Canine Influenza Vaccine, Enhancing Dog Respiratory Protection\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ELAT\">Elanco Animal Health</a> Inc. has received approval from the U.S. Department of Agriculture (USDA) for its TruCan Ultra CIV H3N2/H3N8, a canine influenza vaccine. This vaccine offers broad respiratory protection against the H3N2 and H3N8 strains, making it the only ½ mL bivalent Canine Influenza Virus (CIV) vaccine available with such comprehensive coverage. With 100% virus neutralization against 33 current field isolates and zero lung lesions observed in vaccinated dogs post H3N2 challenge, TruCan Ultra CIV completes Elanco's Tru Portfolio of vaccines. This approval underscores Elanco's commitment to providing innovative animal health solutions, enhancing the health and happiness of pets and their owners.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elanco Animal Health Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DE25259) on July 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4561","symbol_name":"索羅斯持倉","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250709:nNDL4htnFm:1","article_id":"2550313637","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2550313637","pubTimestamp":1752064039,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Elanco Animal Health Inc. Receives USDA Approval for TruCan Ultra CIV Canine Influenza Vaccine, Enhancing Dog Respiratory Protection. Elanco Animal Health Inc. has received approval from the U.S. Department of Agriculture  for its TruCan Ultra CIV H3N2/H3N8, a canine influenza vaccine. This vaccine offers broad respiratory protection against the H3N2 and H3N8 strains, making it the only  mL bivalent Canine Influenza Virus  vaccine available with such comprehensive coverage. With 100% virus neutralization against 33 current field isolates and zero lung lesions observed in vaccinated dogs post H3N2 challenge, TruCan Ultra CIV completes Elanco's Tru Portfolio of vaccines. This approval underscores Elanco's commitment to providing innovative animal health solutions, enhancing the health and happiness of pets and their owners.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4561":"索罗斯持仓","BK4007":"制药","ELAN":"Elanco Animal Health Inc"},"translate_title":"Elanco Animal Health Inc.获得美国农业部批准TruCan Ultra CIV犬流感疫苗，增强狗的呼吸保护","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ELAN":0.9},"content_text":"Elanco Animal Health Inc. Receives USDA Approval for TruCan Ultra CIV Canine Influenza Vaccine, Enhancing Dog Respiratory Protection\n    \n\nElanco Animal Health Inc. has received approval from the U.S. Department of Agriculture (USDA) for its TruCan Ultra CIV H3N2/H3N8, a canine influenza vaccine. This vaccine offers broad respiratory protection against the H3N2 and H3N8 strains, making it the only ½ mL bivalent Canine Influenza Virus (CIV) vaccine available with such comprehensive coverage. With 100% virus neutralization against 33 current field isolates and zero lung lesions observed in vaccinated dogs post H3N2 challenge, TruCan Ultra CIV completes Elanco's Tru Portfolio of vaccines. This approval underscores Elanco's commitment to providing innovative animal health solutions, enhancing the health and happiness of pets and their owners.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elanco Animal Health Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DE25259) on July 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}